Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Corporate presentation posted July 14, 2026 for use in investor meetings.
PALVELLA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Corporate presentation posted July 14, 2026 for use in investor meetings
- Exhibit 99.1 contains the substantive company and pipeline information
- Investor relevance depends on presentation updates to strategy, clinical programs, financing needs, or catalysts
Item EX-99.1 · Exhibit EX-99.1
- NDA submission on track for 2H 2026, with potential FDA approval and U.S. launch in 1H 2027 for microcystic lymphatic malformations
- Phase 3 SELVA delivered statistically significant results across primary, key secondary, and four secondary endpoints, all p<0.001
- Potential first FDA-approved therapy for more than 30,000 diagnosed U.S. patients, with estimated peak sales exceeding $1 billion
- $230 million oversubscribed Q1 2026 financing supports regulatory execution, launch preparation, and pipeline expansion
- Pipeline broadened to six rare diseases across three QTORIN™ programs anticipated by year-end 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PALVELLA THERAPEUTICS, INC. 8-K filings
Get the next PVLA 8-K as it lands
Follow PVLA for push alerts, or ask the research agent what this filing means.